Evaluation of Intravenous Push Piperacillin-Tazobactam on Time to Antibiotic Administration in Emergency Department Patients with Sepsis

J Pharm Pract. 2023 Aug;36(4):756-760. doi: 10.1177/08971900211061937. Epub 2022 Feb 27.

Abstract

Purpose: The purpose of this study was to determine if intravenous push (IVP) administration of piperacillin-tazobactam reduced the time to antibiotic administration compared to intravenous piggyback (IVPB) in emergency department (ED) patients who present with sepsis. Methods: This was a retrospective cohort study of patients with sepsis who received piperacillin-tazobactam before and after implementation of an IVPB to IVP conversion protocol. Results: A total of 486 charts were reviewed and the final analysis included 127 patients in each group. The mean time to administration of piperacillin-tazobactam was 67 (± 48) minutes and 58 (± 36) minutes in the IVPB and IVP cohorts, respectively (P = NS). The time to administration of secondary antibiotics was reduced by 38 minutes in patients who received piperacillin-tazobactam by IVP (105 min ±69 vs 67 min ±37; P < .001). Nurse administration time was reduced by 11 min for piperacillin-tazobactam (54 min ±46 vs 43 min ±33; P = .034) and 40 min for secondary antibiotics (90 min ±67 vs 50 min ±32; P = < .001) in the IVP group. There was no difference in hypersensitivity reactions, hospital length of stay, or mortality. Conclusion: Conversion from piperacillin-tazobactam IVPB to IVP was associated with a reduction in time to piperacillin-tazobactam and secondary antibiotic administration in emergency department patients with sepsis. Further prospective research is needed to evaluate clinical outcomes associated with IVP administration.

Keywords: emergency medicine; intravenous push; piperacillin-tazobactam; sepsis.

MeSH terms

  • Anti-Bacterial Agents
  • Emergency Service, Hospital
  • Humans
  • Penicillanic Acid
  • Piperacillin*
  • Piperacillin, Tazobactam Drug Combination
  • Retrospective Studies
  • Sepsis* / drug therapy

Substances

  • Piperacillin
  • Penicillanic Acid
  • Anti-Bacterial Agents
  • Piperacillin, Tazobactam Drug Combination